Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Effects of L-Arabinose on Intestinal Sucrase Activity in Man
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: University of Copenhagen
Danisco
Information provided by: University of Copenhagen
ClinicalTrials.gov Identifier: NCT00302302
  Purpose

The purpose of this study is to investigate the effect of L-arabinose in a sugar-rich meal on intestinal sucrase activity in healthy volunteers by measuring postprandial blood glucose and insulin, and selected intestinal hormonal responses to increasing doses of L-arabinose.


Condition Intervention Phase
Blood Glucose
Drug: L-arabinose
Phase I

Drug Information available for: Insulin Dextrose Glucagon-like peptide 1 Sucrose
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Dose Comparison, Crossover Assignment, Efficacy Study
Official Title: The Effects of Increasing Doses of L-Arabinose in a Sucrose Rich Meal on Intestinal Sucrase Activity in Man

Further study details as provided by University of Copenhagen:

Primary Outcome Measures:
  • Blood glucose, insulin, triglycerides, GIP and GLP-1

Secondary Outcome Measures:
  • Appetite measurements and energy intake

Enrollment: 15
Study Start Date: September 2005
Estimated Study Completion Date: November 2005
Detailed Description:

Background:

The intake of common table sugar (sucrose) in the industrialised countries is relatively high. In Denmark the daily intake of sugar is in the range of 30-40 g/d exclusive the intake of sugar containing drinks. The health consequences of this relatively high sugar intake are heavily debated in the media. One of the arguments is that a high sugar intake may be one of the factors involved in the development of the metabolic syndrome, including overweight, increased blood glucose and insulin levels as well as impaired insulin action.

L-arabinose is widely distributed in plants and is a common component in plant cell walls in maize, wheat, rye, rice, plant gums etc. The isolated 5-carbon sugar has been shown to suppress the increase of blood glucose and plasma insulin after ingestion of sucrose in rats by inhibition of sucrase activity. In vitro studies on Caco-2 cells indicate that L-arabinose is a potent inhibitor on sucrase activity, possibly in a non-competitive way.

Potential nutritional advantages of consuming L-arabinose in combination with sucrose may therefore be a delayed digestion of sucrose and a lower absorption of glucose, resulting in both lower blood glucose and insulin levels. A delayed digestion of sucrose will reduce the energy utilisation with the potential of reducing weight gain in human subjects.

Methods:

This dose-response study with 14 healthy male volunteers has a randomised cross-over design based on four single "meals" separated by one week wash-out periods. Sugar rich drinks supplemented with different doses of L-arabinose will be tested with respect to postprandial blood glucose, insulin, triglyceride, GIP and GLP-1. Postprandial blood samples will be taken every 15 to 30 min for 180 min. Appetite sensations will be measured every 30 min during the experiment. After 180 minutes an ad libitum lunch will be served and EI will be registered.

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy males
  • BMI between 18.4-25 kg/m2
  • age between 18 and 30

Exclusion Criteria:

  • donation of blood 3 months before or during the study
  • gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease (HIV or hepatitis)
  • smoking
  • consumption of more than 21 alcoholic drinks/week
  • elite athletes
  • on medication
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00302302

Locations
Denmark
Institute of Human Nutrition, The Royal Veterinary and Agricultural University
Frederiksberg, Denmark, DK-1958
Sponsors and Collaborators
University of Copenhagen
Danisco
Investigators
Principal Investigator: Klaus Bukhave, MSc, MScD Institute of Human Nutrition, The Royal Veterinary and Agricultural University, Denmark
  More Information

Study ID Numbers: (KF) 01 270121, M181
Study First Received: September 21, 2005
Last Updated: May 23, 2007
ClinicalTrials.gov Identifier: NCT00302302  
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by University of Copenhagen:
Blood glucose
Insulin
Triglyceride
GIP
GLP-1
L-arabinose
Appetite
Energy intake

Study placed in the following topic categories:
Insulin
Glucagon-Like Peptide 1

ClinicalTrials.gov processed this record on January 16, 2009